An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection

被引:319
作者
Palliser, D
Chowdhury, D
Wang, QY
Lee, SJ
Bronson, RT
Knipe, DM
Lieberman, J [1 ]
机构
[1] Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nature04263
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Herpes simplex virus 2 (HSV-2) infection causes significant morbidity(1) and is an important cofactor for the transmission of HIV infection(2). A microbicide to prevent sexual transmission of HSV-2 would contribute substantially to controlling the spread of HIV and other infections(3,4). Because RNA interference (RNAi) provides effective antiviral defence in plants and other organisms, several studies have focused on harnessing RNAi to inhibit viral infection(5). Here we show that vaginal instillation of small interfering RNAs (siRNAs) targeting HSV-2 protects mice from lethal infection. siRNAs mixed with lipid are efficiently taken up by epithelial and lamina propria cells and silence gene expression in the mouse vagina and ectocervix for at least nine days. Intravaginal application of siRNAs targeting the HSV-2 UL27 and UL29 genes ( which encode an envelope glycoprotein and a DNA binding protein(6), respectively) was well tolerated, did not induce interferon-responsive genes or cause inflammation, and protected mice when administered before and/or after lethal HSV-2 challenge. These results suggest that siRNAs are attractive candidates for the active component of a microbicide designed to prevent viral infection or transmission.
引用
收藏
页码:89 / 94
页数:6
相关论文
共 29 条
  • [11] Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
    Judge, AD
    Sood, V
    Shaw, JR
    Fang, D
    McClintock, K
    MacLachlan, I
    [J]. NATURE BIOTECHNOLOGY, 2005, 23 (04) : 457 - 462
  • [12] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [13] Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8
  • [14] Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque
    Li, BJ
    Tang, QQ
    Cheng, D
    Qin, C
    Xie, FY
    Wei, Q
    Xu, J
    Liu, YJ
    Zheng, BJ
    Woodle, MC
    Zhong, NS
    Lu, PY
    [J]. NATURE MEDICINE, 2005, 11 (09) : 944 - 951
  • [15] RNA interference and chemically modified small interfering RNAs
    Manoharan, M
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2004, 8 (06) : 570 - 579
  • [16] MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163
  • [17] Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge
    Morrison, LA
    Da Costa, XJ
    Knipe, DM
    [J]. VIROLOGY, 1998, 243 (01) : 178 - 187
  • [18] siRNA-directed inhibition of HIV-1 infection
    Novina, CD
    Murray, MF
    Dykxhoorn, DM
    Beresford, PJ
    Riess, J
    Lee, SK
    Collman, RG
    Lieberman, J
    Shankar, P
    Sharp, PA
    [J]. NATURE MEDICINE, 2002, 8 (07) : 681 - 686
  • [19] Starting to gel
    Pilcher, H
    [J]. NATURE, 2004, 430 (6996) : 138 - 140
  • [20] Roizman B., 2001, FIELDS VIROLOGY, V2, P2399